{"nctId":"NCT00459056","briefTitle":"The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients","startDateStruct":{"date":"2007-04"},"conditions":["Abdominal Obesity","Hypertension"],"count":25,"armGroups":[{"label":"Carvediolol CR + Lisinopril, then Lisinopril + HCTZ","type":"EXPERIMENTAL","interventionNames":["Drug: Carvedilol CR + Lisinopril","Drug: Lisinopril + HCTZ"]},{"label":"Lisinopril + HCTZ, then Carvedilol CR + Lisinopril","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Carvedilol CR + Lisinopril","Drug: Lisinopril + HCTZ"]}],"interventions":[{"name":"Carvedilol CR + Lisinopril","otherNames":["Prinivil","Coreg"]},{"name":"Lisinopril + HCTZ","otherNames":["Prinivil","Hydrochlorothiazide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* \\>18 years old\n* Systolic blood pressure (SBP) \\>130 and/or diastolic blood pressure (DBP) \\>85 (or currently taking anti-hypertensive medication)\n* Waist circumference \\>102 cm (men) and \\>88 cm (women)\n* Stable cardiovascular medication regimen (or other medications known to affect endothelial function) at least 1 month prior to enrollment and throughout the study\n\nExclusion Criteria:\n\n* Use of anti-hypertensive medications within one month of randomization (patients may be washed-out from anti-hypertensive medications)\n* Unstable angina\n* History of angina symptoms within 3 months of screening\n* Decompensated heart failure\n* History of myocardial infarction\n* Stroke or coronary artery bypass graft within 3 months of screening\n* Standard clinical contraindications to beta-blocker therapy\n* Standard clinical contraindications to ACE-I therapy\n* Women who are currently pregnant or planning to become pregnant (pregnancy testing will occur at specific intervals throughout study and women will be informed of potential risks during the consenting process; information specific to this risk will be detailed in the consent form)\n* Breastfeeding women\n* Clinically significant liver disease\n* Creatinine \\> 2.5 mg/dL\n* Hepatic function greater than 3 times upper limit of normal","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Reactive Hyperemic Index by Period (Carvedilol CR + Lisinopril vs. Lisinopril + HCTZ)","description":"Reactive hyperemic index is a measure of endothelial function. This is measured by the ratio of post-occlusion blood volume flow versus the baseline blood volume flow. The outcome reported is the change in this ratio after the first intervention phase compared to after the second intervention phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.59"},{"groupId":"OG001","value":"-0.14","spread":"0.18"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}